0.2736 USD
+0.01 (+1.94%)
0.281 USD
+0.01 (+2.7%)
AKTX gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 525 industry peers in the Biotechnology industry. Both the profitability and financial health of AKTX have multiple concerns. AKTX has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
- In the past year AKTX has reported negative net income.
- AKTX had a negative operating cash flow in the past year.
- In the past 5 years AKTX always reported negative net income.
- In the past 5 years AKTX always reported negative operating cash flow.
1.2 Ratios
- Looking at the Return On Assets, with a value of -34.76%, AKTX is in the better half of the industry, outperforming 62.67% of the companies in the same industry.
- AKTX has a Return On Equity of -69.52%. This is comparable to the rest of the industry: AKTX outperforms 56.57% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -34.76% | ||
| ROE | -69.52% | ||
| ROIC | N/A |
ROA(3y)-132.43%
ROA(5y)-132.76%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Profit Margin and Operating Margin and Gross Margin are not available for AKTX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- The debt/assets ratio for AKTX is higher compared to a year ago.
2.2 Solvency
- Based on the Altman-Z score of -7.42, we must say that AKTX is in the distress zone and has some risk of bankruptcy.
- Looking at the Altman-Z score, with a value of -7.42, AKTX is doing worse than 66.48% of the companies in the same industry.
- AKTX has a Debt/Equity ratio of 0.09. This is a healthy value indicating a solid balance between debt and equity.
- The Debt to Equity ratio of AKTX (0.09) is worse than 62.10% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -7.42 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
- A Current Ratio of 0.19 indicates that AKTX may have some problems paying its short term obligations.
- AKTX's Current ratio of 0.19 is on the low side compared to the rest of the industry. AKTX is outperformed by 93.33% of its industry peers.
- AKTX has a Quick Ratio of 0.19. This is a bad value and indicates that AKTX is not financially healthy enough and could expect problems in meeting its short term obligations.
- AKTX has a worse Quick ratio (0.19) than 93.14% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.19 | ||
| Quick Ratio | 0.19 |
3. Growth
3.1 Past
- AKTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 84.21%, which is quite impressive.
EPS 1Y (TTM)84.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
- The Earnings Per Share is expected to grow by 24.37% on average over the next years. This is a very strong growth
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y94.04%
EPS Next 2Y39.27%
EPS Next 3Y24.37%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
- AKTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AKTX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- AKTX's earnings are expected to grow with 24.37% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.27%
EPS Next 3Y24.37%
5. Dividend
5.1 Amount
- No dividends for AKTX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
AKARI THERAPEUTICS PLC-ADR / AKTX FAQ
What is the ChartMill fundamental rating of AKARI THERAPEUTICS PLC-ADR (AKTX) stock?
ChartMill assigns a fundamental rating of 1 / 10 to AKTX.
Can you provide the valuation status for AKARI THERAPEUTICS PLC-ADR?
ChartMill assigns a valuation rating of 1 / 10 to AKARI THERAPEUTICS PLC-ADR (AKTX). This can be considered as Overvalued.
What is the profitability of AKTX stock?
AKARI THERAPEUTICS PLC-ADR (AKTX) has a profitability rating of 1 / 10.
Can you provide the financial health for AKTX stock?
The financial health rating of AKARI THERAPEUTICS PLC-ADR (AKTX) is 0 / 10.